58
Participants
Start Date
February 8, 2024
Primary Completion Date
April 30, 2026
Study Completion Date
January 31, 2028
Allogeneic cytomegalovirus-specific T cells
Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors
Pembrolizumab
A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
NOT_YET_RECRUITING
Austin Hospital, Heidelberg
RECRUITING
Newro Foundation, Bowen Hills
NOT_YET_RECRUITING
Royal Brisbane and Women's Hospital, Herston
NOT_YET_RECRUITING
Princess Alexandra Hospital, Woolloongabba
Collaborators (1)
CUREator
UNKNOWN
Merck Sharp & Dohme LLC
INDUSTRY
The Newro Foundation
UNKNOWN
Royal Brisbane and Women's Hospital
OTHER_GOV
Princess Alexandra Hospital, Brisbane, Australia
OTHER
Austin Hospital, Melbourne Australia
OTHER
Queensland Institute of Medical Research
OTHER